Generation Bio GBIO 深 沪
已收盘 08-01 16:00:00 美东时间
4.21
-0.230
-5.18%
华盛通- 最 高4.395
- 今 开4.33
- 成交量 14.39万股
- 最 低 4.11
- 昨 收 4.44
- 总市值 2.82亿
- 52周最高 29.40
- 市盈率 静 --
- 换手率 0.21%
- 52周最低 3.004
- 委 比 -39.86%
- 总股本 6703.52万
- 历史最高 557.20
- 量 比 1.03
- 振 幅 6.42%
- 历史最低 3.004
- 每 手 1
- 风险率 8.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Generation Bio shares are trading higher after the company announced it has been granted Australian Patent Number 2019210034 titled "Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors (for gene therapy)"
Generation Bio shares are trading higher after the company announced it has bee...
07-26 02:44
Generation Bio shares are trading lower after the company announced a 1-for-10 reverse stock split.
Generation Bio shares are trading lower after the company announced a 1-for-10 ...
07-18 22:51
Generation Bio Announces 1-for-10 Reverse Stock Split
Generation Bio announced a 1-for-10 reverse stock split to increase its share price and regain compliance with Nasdaq listing requirements. Effective July 21, 2025, every 10 shares will be combined into 1 share, reducing outstanding shares from ~67.3M to ~6.7M. The stock will resume trading on July 22 under the same symbol "GBIO" with a new CUSIP. Adjustments will be made to equity plans, and fractional shares will be paid in cash. The goal is to...
07-18 12:35
Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Generation Bio Co. granted 128,600 non-statutory stock options to a new employee on July 1, 2025, under its 2025 Inducement Stock Incentive Plan. The options have an exercise price of $0.32 per share, a 10-year term, and vest over four years, with 25% vesting on the first anniversary and 6.25% quarterly thereafter. The company specializes in treating T cell-driven autoimmune diseases by reprogramming T cells to reduce autoreactive cells using lip...
07-07 20:05
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
Generation Bio Co. (Nasdaq:GBIO) announced that its CEO, Geoff McDonough, M.D., will present at the Jefferies Global Healthcare Conference on June 4th. The presentation will focus on the company's work to treat T cell-driven autoimmune diseases by reprogramming T cells using lipid nanoparticles (ctLNP) to deliver siRNA, targeting disease-driving genes. A live webcast and replay will be available on the company's investor website. --- Generation...
05-28 10:59
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 79.5% to $0.4...
05-09 20:10
Where Generation Bio Stands With Analysts
Across the recent three months, 4 analysts have shared their insights on Genera...
05-09 06:01
Needham Reiterates Buy on Generation Bio, Maintains $8 Price Target
Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:GBIO) with a Buy and maintains $8 price target.
05-08 19:56
Generation Bio Q1 EPS $(0.22) Beats $(0.29) Estimate, Sales $8.72M Beat $2.13M Estimate
Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.29) by 24.14 percent. This is a 80.36 percent increase over losses of $(1.12) per share from
05-08 04:58
Generation Bio Granted U.S. Patent #12263228 : Lipids and compositions thereof.
https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12263228
04-02 02:42
